Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
CAR-T cell therapy for ALL: Current challenges and future approaches ( Dr Sara Ghorashian - University College London, London, UK )
23 Jan 2020
Considerations for treatment sequencing in B-ALL
Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany
Considerations for treatment sequencing in B-ALL ( Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany )
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
CART-T cell therapy in young patients with relapsed/refractory ALL ( Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany )
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Defining the role of immunotherapy in B-cell ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, U...
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-pos...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020